Courtney Flaherty

Articles

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer

May 17th 2024

Dose reductions of ribociclib plus an NSAI did not decrease the regimen’s efficacy in patients with HR-positive, HER2-negative early breast cancer.

FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC

May 17th 2024

NVL-655 has received FDA breakthrough therapy designation for patients with pretreated ALK-positive non-small cell lung cancer.

T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer

May 16th 2024

Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.

Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer

May 15th 2024

Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant, ER-positive, HER2-negative breast cancer.

Grivas Spotlights Advances With Immunotherapy-Based Approaches in Urothelial Cancer

May 14th 2024

Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.

Petosemtamab Receives FDA Breakthrough Therapy Designation in Pretreated HNSCC

May 13th 2024

The FDA has granted breakthrough therapy designation to petosemtamab in recurrent or metastatic head and neck squamous cell carcinoma.

EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer

May 10th 2024

Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.

SNB-101 Receives FDA Fast Track Designation for SCLC

May 10th 2024

SNB-101 has received FDA fast track designation for potential use in patients with small cell lung cancer.

Additional 3 Years of Adjuvant Imatinib Maintenance Reduces Recurrence Risk in High-Risk GIST

May 9th 2024

Prolonged administration of imatinib maintenance therapy for 6 years improved disease-free survival in patients with gastrointestinal stromal tumors.

Naumann Dives into Case-by-Case Decision-Making in Ovarian and Endometrial Cancer

May 8th 2024

R. Wendel Naumann, MD, highlights endometrial cancer case studies and how they represent changes in this treatment paradigm.

TSP May Predict Chemoresistance and Survival Outcomes in Ovarian Cancer

May 8th 2024

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic use of tumor stroma proportion for outcomes and chemoresistance in ovarian cancer.

Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer

May 7th 2024

R. Wendel Naumann, MD, discusses 2 case studies in platinum-resistant ovarian cancer and the optimal treatment approaches for each patient.

Orca-T Offers Favorable Post-Transplant Outcomes in Advanced Hematologic Malignancies

May 7th 2024

Amandeep Salhotra, MD, discusses the feasibility and safety of Orca-T graft in patients undergoing allogeneic transplant for hematologic malignancies.

NXC-201 Receives Orphan Drug Designation in the European Union for Multiple Myeloma

May 3rd 2024

The CAR T-cell therapy NXC-201 has received orphan drug designation from the European Commission for patients with multiple myeloma.

N-803/BCG Approval Signals Paradigm Shift in Management of BCG-Unresponsive NMIBC

May 1st 2024

Karim Chamie, MD, discusses the significance of the FDA approval of N-803 plus BCG in BCG-unresponsive non–muscle invasive bladder cancer.

Chidamide Plus R-CHOP Approved in China for MYC/BCL2–Expressing DLBCL

April 30th 2024

Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.

Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC

April 29th 2024

Samer A. Srour, MB ChB, MS, explains the significance of early safety and efficacy data with CTX130 in CD70-expressing clear cell renal cell carcinoma.

Garje Elucidates Biomarker-Driven Approaches Generating Excitement in Metastatic Prostate Cancer

April 26th 2024

Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.

Comparable Germline Variant Rates Seen Across Racial Groups in Metastatic Prostate Cancer

April 26th 2024

Kara N. Maxwell, MD, PhD, discusses the prevalence of germline mutations in racially diverse cohorts of patients with metastatic prostate cancer.

Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection

April 25th 2024

Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.